JP2015510770A - 組換えペプチドの産生方法 - Google Patents
組換えペプチドの産生方法 Download PDFInfo
- Publication number
- JP2015510770A JP2015510770A JP2015500714A JP2015500714A JP2015510770A JP 2015510770 A JP2015510770 A JP 2015510770A JP 2015500714 A JP2015500714 A JP 2015500714A JP 2015500714 A JP2015500714 A JP 2015500714A JP 2015510770 A JP2015510770 A JP 2015510770A
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- vsdl
- fusion polypeptide
- cleavage site
- trypsin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 543
- 238000004519 manufacturing process Methods 0.000 title claims description 21
- 230000004927 fusion Effects 0.000 claims abstract description 287
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 263
- 229920001184 polypeptide Polymers 0.000 claims abstract description 212
- 229940124549 vasodilator Drugs 0.000 claims abstract description 131
- 239000003071 vasodilator agent Substances 0.000 claims abstract description 131
- 230000007030 peptide scission Effects 0.000 claims abstract description 103
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 70
- 238000000034 method Methods 0.000 claims abstract description 54
- 238000003776 cleavage reaction Methods 0.000 claims description 183
- 230000007017 scission Effects 0.000 claims description 183
- 108010090012 atrial natriuretic factor prohormone (31-67) Proteins 0.000 claims description 123
- 108090000631 Trypsin Proteins 0.000 claims description 114
- 102000004142 Trypsin Human genes 0.000 claims description 114
- 239000012588 trypsin Substances 0.000 claims description 114
- 108091005601 modified peptides Proteins 0.000 claims description 88
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 48
- 210000004899 c-terminal region Anatomy 0.000 claims description 45
- 210000004027 cell Anatomy 0.000 claims description 44
- 150000001413 amino acids Chemical class 0.000 claims description 36
- 239000002773 nucleotide Substances 0.000 claims description 29
- 125000003729 nucleotide group Chemical group 0.000 claims description 29
- 239000004475 Arginine Substances 0.000 claims description 27
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 27
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims description 24
- 241000588724 Escherichia coli Species 0.000 claims description 17
- 102000004190 Enzymes Human genes 0.000 claims description 15
- 108090000790 Enzymes Proteins 0.000 claims description 15
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 15
- 239000004472 Lysine Substances 0.000 claims description 14
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims description 13
- 230000001810 trypsinlike Effects 0.000 claims description 12
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 9
- 101800001415 Bri23 peptide Proteins 0.000 claims description 9
- 102400000107 C-terminal peptide Human genes 0.000 claims description 9
- 101800000655 C-terminal peptide Proteins 0.000 claims description 9
- 238000003259 recombinant expression Methods 0.000 claims description 4
- 238000005349 anion exchange Methods 0.000 claims description 3
- 108010091748 peptide A Proteins 0.000 claims description 3
- 238000001694 spray drying Methods 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 51
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 46
- 235000001014 amino acid Nutrition 0.000 description 42
- 229940024606 amino acid Drugs 0.000 description 34
- 239000013592 cell lysate Substances 0.000 description 32
- 108090000623 proteins and genes Proteins 0.000 description 23
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- 238000000746 purification Methods 0.000 description 19
- 239000013612 plasmid Substances 0.000 description 16
- 239000011347 resin Substances 0.000 description 15
- 229920005989 resin Polymers 0.000 description 15
- 239000007983 Tris buffer Substances 0.000 description 14
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 13
- 239000013638 trimer Substances 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 12
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 12
- 230000029087 digestion Effects 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 12
- 235000018977 lysine Nutrition 0.000 description 12
- 238000006467 substitution reaction Methods 0.000 description 11
- 241000196324 Embryophyta Species 0.000 description 10
- 229930027917 kanamycin Natural products 0.000 description 10
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 10
- 229960000318 kanamycin Drugs 0.000 description 10
- 229930182823 kanamycin A Natural products 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 10
- 238000000926 separation method Methods 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 9
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 9
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 239000012528 membrane Substances 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 7
- 102400001282 Atrial natriuretic peptide Human genes 0.000 description 7
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 7
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 7
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 7
- 239000003957 anion exchange resin Substances 0.000 description 7
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 7
- 239000002934 diuretic Substances 0.000 description 7
- 238000010828 elution Methods 0.000 description 7
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 7
- 238000004007 reversed phase HPLC Methods 0.000 description 7
- 239000001632 sodium acetate Substances 0.000 description 7
- 235000017281 sodium acetate Nutrition 0.000 description 7
- 108010054278 Lac Repressors Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000012535 impurity Substances 0.000 description 6
- 210000003734 kidney Anatomy 0.000 description 6
- 101150109249 lacI gene Proteins 0.000 description 6
- 230000010076 replication Effects 0.000 description 6
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 238000013518 transcription Methods 0.000 description 6
- 230000035897 transcription Effects 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000000356 contaminant Substances 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000002158 endotoxin Substances 0.000 description 5
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000003960 organic solvent Substances 0.000 description 5
- 108091033319 polynucleotide Proteins 0.000 description 5
- 102000040430 polynucleotide Human genes 0.000 description 5
- 239000002157 polynucleotide Substances 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 241000283690 Bos taurus Species 0.000 description 4
- 241000699800 Cricetinae Species 0.000 description 4
- 108010063738 Interleukins Proteins 0.000 description 4
- 102000015696 Interleukins Human genes 0.000 description 4
- 241000235058 Komagataella pastoris Species 0.000 description 4
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 4
- 238000005571 anion exchange chromatography Methods 0.000 description 4
- 230000004071 biological effect Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 238000011031 large-scale manufacturing process Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 230000001452 natriuretic effect Effects 0.000 description 4
- 210000001672 ovary Anatomy 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000002441 reversible effect Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 4
- 206010007559 Cardiac failure congestive Diseases 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 206010019280 Heart failures Diseases 0.000 description 3
- 101500027333 Homo sapiens Vessel dilator Proteins 0.000 description 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 3
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000036772 blood pressure Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000013375 chromatographic separation Methods 0.000 description 3
- 108090001092 clostripain Proteins 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000001882 diuretic effect Effects 0.000 description 3
- 239000013604 expression vector Substances 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 3
- 230000000004 hemodynamic effect Effects 0.000 description 3
- 235000014304 histidine Nutrition 0.000 description 3
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 235000006109 methionine Nutrition 0.000 description 3
- 229930182817 methionine Natural products 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000000178 monomer Substances 0.000 description 3
- 239000002952 polymeric resin Substances 0.000 description 3
- 229920003053 polystyrene-divinylbenzene Polymers 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 229920003002 synthetic resin Polymers 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- NQUNIMFHIWQQGJ-UHFFFAOYSA-N 2-nitro-5-thiocyanatobenzoic acid Chemical compound OC(=O)C1=CC(SC#N)=CC=C1[N+]([O-])=O NQUNIMFHIWQQGJ-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 241000228257 Aspergillus sp. Species 0.000 description 2
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 2
- 239000002028 Biomass Substances 0.000 description 2
- 101001002617 Bos taurus Interleukin-2 Proteins 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 241000589774 Pseudomonas sp. Species 0.000 description 2
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 2
- 241001147693 Staphylococcus sp. Species 0.000 description 2
- 241000187180 Streptomyces sp. Species 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 238000013019 agitation Methods 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000011210 chromatographic step Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 2
- 235000018417 cysteine Nutrition 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 230000002538 fungal effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 235000014705 isoleucine Nutrition 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 230000020477 pH reduction Effects 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 235000008729 phenylalanine Nutrition 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- CJNZAXGUTKBIHP-UHFFFAOYSA-N 2-iodobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1I CJNZAXGUTKBIHP-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100026189 Beta-galactosidase Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 102000004018 Caspase 6 Human genes 0.000 description 1
- 108090000425 Caspase 6 Proteins 0.000 description 1
- 108090000567 Caspase 7 Proteins 0.000 description 1
- 102100035904 Caspase-1 Human genes 0.000 description 1
- 108090000426 Caspase-1 Proteins 0.000 description 1
- 102000004068 Caspase-10 Human genes 0.000 description 1
- 108090000572 Caspase-10 Proteins 0.000 description 1
- 102000004046 Caspase-2 Human genes 0.000 description 1
- 108090000552 Caspase-2 Proteins 0.000 description 1
- 102100029855 Caspase-3 Human genes 0.000 description 1
- 102100025597 Caspase-4 Human genes 0.000 description 1
- 101710090338 Caspase-4 Proteins 0.000 description 1
- 102100038916 Caspase-5 Human genes 0.000 description 1
- 101710090333 Caspase-5 Proteins 0.000 description 1
- 102100038902 Caspase-7 Human genes 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 108090000538 Caspase-8 Proteins 0.000 description 1
- 102100026550 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 108091028732 Concatemer Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 102000001477 Deubiquitinating Enzymes Human genes 0.000 description 1
- 108010093668 Deubiquitinating Enzymes Proteins 0.000 description 1
- 101710158332 Diuretic hormone Proteins 0.000 description 1
- 101710204261 Diuretic hormone class 2 Proteins 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108010051815 Glutamyl endopeptidase Proteins 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 101710170453 Glycoprotein 55 Proteins 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 101000882911 Hathewaya histolytica Clostripain Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101500028775 Homo sapiens Glucagon Proteins 0.000 description 1
- 101500027330 Homo sapiens Kaliuretic peptide Proteins 0.000 description 1
- 101000780028 Homo sapiens Natriuretic peptides A Proteins 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102000056251 Prolyl Oligopeptidases Human genes 0.000 description 1
- 108700015930 Prolyl Oligopeptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101800004937 Protein C Proteins 0.000 description 1
- 239000012564 Q sepharose fast flow resin Substances 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 102400000827 Saposin-D Human genes 0.000 description 1
- 101800001700 Saposin-D Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 108090001109 Thermolysin Proteins 0.000 description 1
- 102100036407 Thioredoxin Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 102400000757 Ubiquitin Human genes 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- -1 acts Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 230000001746 atrial effect Effects 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- ZOOGRGPOEVQQDX-UHFFFAOYSA-N cyclic GMP Natural products O1C2COP(O)(=O)OC2C(O)C1N1C=NC2=C1NC(N)=NC2=O ZOOGRGPOEVQQDX-UHFFFAOYSA-N 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 150000003109 potassium Chemical class 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 108010064037 prorennin Proteins 0.000 description 1
- 229960000856 protein c Drugs 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000013017 sartobind Substances 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000002305 strong-anion-exchange chromatography Methods 0.000 description 1
- 108010059339 submandibular proteinase A Proteins 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229940094937 thioredoxin Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000009261 transgenic effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 108010036927 trypsin-like serine protease Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 230000024883 vasodilation Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/58—Atrial natriuretic factor complex; Atriopeptin; Atrial natriuretic peptide [ANP]; Cardionatrin; Cardiodilatin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261612817P | 2012-03-19 | 2012-03-19 | |
| US61/612,817 | 2012-03-19 | ||
| PCT/AU2013/000273 WO2013138850A1 (en) | 2012-03-19 | 2013-03-19 | Method of producing a recombinant peptide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015510770A true JP2015510770A (ja) | 2015-04-13 |
| JP2015510770A5 JP2015510770A5 (enExample) | 2016-05-19 |
Family
ID=49221695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015500714A Pending JP2015510770A (ja) | 2012-03-19 | 2013-03-19 | 組換えペプチドの産生方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20150315259A1 (enExample) |
| EP (1) | EP2839010B1 (enExample) |
| JP (1) | JP2015510770A (enExample) |
| KR (1) | KR20140148420A (enExample) |
| CN (2) | CN107266554A (enExample) |
| AU (2) | AU2013234860B2 (enExample) |
| SG (1) | SG11201405721VA (enExample) |
| WO (1) | WO2013138850A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8947194B2 (en) | 2009-05-26 | 2015-02-03 | Solaredge Technologies Ltd. | Theft detection and prevention in a power generation system |
| EP3773669A4 (en) * | 2018-03-29 | 2022-04-27 | Contrafect Corporation | ANTIMICROBIAL BACTERIOPHAGE-DERIVED POLYPEPTIDES AND THEIR USE AGAINST GRAM-NEGATIVE BACTERIA |
| CN113121637B (zh) * | 2020-01-15 | 2022-06-14 | 鲁南制药集团股份有限公司 | 一种重组蛋白的分离纯化方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001512745A (ja) * | 1997-08-07 | 2001-08-28 | クリエイティヴ・ペプティドス・スウェーデン・アクチエボラーグ | インスリンｃ−ペプチドの組換え発現 |
| JP2004519417A (ja) * | 2000-06-30 | 2004-07-02 | ベクトン・ディキンソン・アンド・カンパニー | 培地用ペプチド |
| JP2006508639A (ja) * | 2002-05-24 | 2006-03-16 | リストレイジェン・インコーポレイテッド | ポリペプチドの高収率生産のための方法およびｄｎａ構築物 |
| WO2009040031A2 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| US20110008827A1 (en) * | 2008-06-18 | 2011-01-13 | Isfahan University Of Technology | Method to produce recombinant MBP8298 and other polypeptides by nucleotide structure optimization |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5691310A (en) | 1987-09-29 | 1997-11-25 | Vesely; David L. | Methods of treatment using proANF peptides |
| ES2263278T3 (es) * | 1998-07-10 | 2006-12-01 | Scios Inc. | Metodo para producir un peptido con un pl por encima de 8 o por debajo de 5. |
| WO2000017336A1 (en) * | 1998-09-19 | 2000-03-30 | Sang Jun Lee | Dna cassette encoding a multimer of a biologically active peptide and a cleavable linker attached thereto and process for preparing the biologically active peptide |
| CN1363654A (zh) * | 2001-07-19 | 2002-08-14 | 上海华谊生物技术有限公司 | 生产促胰岛素分泌肽glp－1(7－36)的基因工程菌以及生产glp－1(7－36)的方法 |
| DE60331584D1 (de) * | 2002-11-26 | 2010-04-15 | Biocon Ltd | Modifizierte natriuretic verbindungen, konjugate und ihre verwendungen |
| WO2005094420A2 (en) * | 2004-02-17 | 2005-10-13 | University Of South Florida | Materials and methods for treatment of inflammatory and cell proliferation disorders |
| EP1736480B9 (en) * | 2005-06-02 | 2009-03-04 | Polyquant GmbH | Artificial protein, method for absolute quantification of proteins and uses thereof |
| RU2451750C2 (ru) * | 2007-09-24 | 2012-05-27 | Общество С Ограниченной Ответственностью "Герофарм" | Способ получения рекомбинантного с-пептида проинсулина человека |
| JP2013505013A (ja) * | 2009-09-18 | 2013-02-14 | セレクシス エス．エー． | 強化導入遺伝子発現およびプロセッシングの産物および方法 |
| WO2012019237A1 (en) * | 2010-08-12 | 2012-02-16 | Madeleine Pharmaceuticals Pty Ltd | Therapeutic method for treating congestive heart failure |
| WO2012115772A2 (en) * | 2011-02-25 | 2012-08-30 | Medtronic, Inc. | Therapy for kidney disease and/or heart failure |
-
2013
- 2013-03-19 JP JP2015500714A patent/JP2015510770A/ja active Pending
- 2013-03-19 US US14/385,402 patent/US20150315259A1/en not_active Abandoned
- 2013-03-19 CN CN201710409638.4A patent/CN107266554A/zh active Pending
- 2013-03-19 EP EP13765199.8A patent/EP2839010B1/en active Active
- 2013-03-19 KR KR1020147029054A patent/KR20140148420A/ko not_active Withdrawn
- 2013-03-19 WO PCT/AU2013/000273 patent/WO2013138850A1/en not_active Ceased
- 2013-03-19 AU AU2013234860A patent/AU2013234860B2/en not_active Ceased
- 2013-03-19 CN CN201380025049.6A patent/CN104364378A/zh active Pending
- 2013-03-19 SG SG11201405721VA patent/SG11201405721VA/en unknown
-
2016
- 2016-02-29 AU AU2016100212A patent/AU2016100212A4/en not_active Ceased
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001512745A (ja) * | 1997-08-07 | 2001-08-28 | クリエイティヴ・ペプティドス・スウェーデン・アクチエボラーグ | インスリンｃ−ペプチドの組換え発現 |
| JP2004519417A (ja) * | 2000-06-30 | 2004-07-02 | ベクトン・ディキンソン・アンド・カンパニー | 培地用ペプチド |
| JP2006508639A (ja) * | 2002-05-24 | 2006-03-16 | リストレイジェン・インコーポレイテッド | ポリペプチドの高収率生産のための方法およびｄｎａ構築物 |
| WO2009040031A2 (en) * | 2007-09-11 | 2009-04-02 | Mondobiotech Laboratories Ag | Use of a peptide as a therapeutic agent |
| US20110008827A1 (en) * | 2008-06-18 | 2011-01-13 | Isfahan University Of Technology | Method to produce recombinant MBP8298 and other polypeptides by nucleotide structure optimization |
Non-Patent Citations (1)
| Title |
|---|
| SANG JUN LEE, ET AL, MOLECULES AND CELLS, vol. 10, no. 2, JPN6017013630, 2000, pages 236 - 240 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104364378A (zh) | 2015-02-18 |
| EP2839010B1 (en) | 2018-04-25 |
| AU2016100212A4 (en) | 2016-04-14 |
| CN107266554A (zh) | 2017-10-20 |
| EP2839010A4 (en) | 2015-12-09 |
| KR20140148420A (ko) | 2014-12-31 |
| EP2839010A1 (en) | 2015-02-25 |
| US20150315259A1 (en) | 2015-11-05 |
| WO2013138850A1 (en) | 2013-09-26 |
| AU2013234860A1 (en) | 2014-10-16 |
| SG11201405721VA (en) | 2014-10-30 |
| AU2013234860B2 (en) | 2016-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20140213514A1 (en) | Insulin production methods and pro-insulin constructs | |
| WO2014165093A9 (en) | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto | |
| CN104619726A (zh) | 由超折叠绿色荧光蛋白构成的融合蛋白及其用途 | |
| US20100145033A1 (en) | Novel orthogonal process for purification of recombinant human parathyroid hormone (rhpth) (1-34) | |
| CN114591415B (zh) | Glp-1/gcg双受体激动剂多肽及其融合蛋白 | |
| CN101967493A (zh) | 一种原核表达载体及其应用 | |
| AU2016100212A4 (en) | Method of producing a recombinant peptide | |
| Lin et al. | Facile expression and purification of active human growth hormone in E. coli by a cleavable self-aggregating tag scheme | |
| CN104387473B (zh) | 用于非酶切非色谱纯化方法原核表达融合蛋白Prx的类弹性蛋白多肽ELP | |
| JP7266325B2 (ja) | 蛍光タンパク質フラグメントを含む融合タンパク質およびその用途 | |
| EP2956468A1 (en) | Tangential flow filtration based protein refolding methods | |
| US11267863B2 (en) | N-terminal fusion partner for producing recombinant polypeptide, and method for producing recombinant polypeptide using same | |
| KR102345011B1 (ko) | GroES 융합을 이용한 글루카곤 유사 펩타이드-1 또는 이의 유사체의 생산방법 | |
| WO2016161983A1 (zh) | 一种融合载体蛋白及其在促进目的蛋白或多肽表达中的应用 | |
| US11179444B2 (en) | Glucagon analogs and methods of use thereof | |
| CN118344462B (zh) | 一种用于肺部给药的索马鲁肽突变体、融合蛋白及相关产品 | |
| CN108707193A (zh) | 一种表达纯化重组cxcl9蛋白的方法及其应用 | |
| CN100418983C (zh) | 人胰高血糖素相关肽-2类似物 | |
| KR20210071859A (ko) | 펩타이드 및 단백질 생산용 융합태그 | |
| KR102345013B1 (ko) | GroES 융합을 이용한 글루카곤 유사 펩타이드-2 또는 이의 유사체의 생산방법 | |
| MX2014010082A (es) | Metodo para la reduccion de desplazamientos del marco de lectura 1->2. | |
| WO2025077918A1 (zh) | 一种重组多肽以及制备神经毒素的方法 | |
| HK40072579B (zh) | 一种胰岛素或其类似物前体 | |
| KR20210063309A (ko) | GroES 융합을 이용한 인간부갑상선호르몬 1-34의 생산방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160317 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20160317 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160419 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160621 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170516 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170530 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170629 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171012 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20180307 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20181204 |